Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.

Slides:

Advertisements

Similar presentations

Johan Denollet, PhD the heart failure patient ? Why is a dedicated cardiologist not sufficient for The Netherlands.

Advertisements

Hypertrophic Cardiomyopathy Guidelines Summary from the: ACC/ESC Clinical Expert Consensus Statement on Hypertrophic Cardiomyopathy Maron BJ, et al. J.

Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)

Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,

Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.

PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.

Jennifer Cohen, MD, Heather Costa, PhD, Robert Russo, MD, PhD, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA The MagnaSafe Registry:

1 Clinical Overview of Atrial Fibrillation Edward L.C. Pritchett, M.D. Consulting Professor of Medicine Divisions of Cardiology and Clinical Pharmacology.

Cardioversion of Atrial Fibrillation Clinical Issues Christopher Granger, MD Director, Cardiac Care Unit Duke University Medical Center December 2007.

Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,

Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.

Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.

Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.

Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.

Patient education tools are key to the follow- up of chronic heart failure patients.

Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.

Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.

New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology

IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.

Adverse Outcomes After Hospitalization and Delirium in Persons with Alzheimer Disease Charles Wang, PharmD Candidate.

Quality of life in patients with implantable cardioverter defibrillators Author: Camelia Tănăsuc Coordinator: Professor Doctor Dan Dobreanu Coauthors:

Introduction Most patients undergoing left ventricular assist device (LVAD) implantation for destination therapy (DT) also have an implantable cardioverter.

Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.

The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.

CoRPS Center of Research on Psychology in Somatic diseases Depression and anxiety in atrial fibrillation patients - is this undertreated? Susanne S. Pedersen,

CoRPS Center of Research on Psychology in Somatic diseases Quality of life. How to evaluate? Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases Cardiac Psychology: A match made in heaven for patients Susanne S. Pedersen, Professor of Cardiac.

CoRPS Center of Research on Psychology in Somatic diseases E-health for implantable cardioverter defibrillator patients to improve secondary prevention:

CoRPS Center of Research on Psychology in Somatic diseases The Medtronic Sprint Fidelis lead advisory notification has no adverse impact on patient reported.

CoRPS Center of Research on Psychology in Somatic diseases Positive and negative emotions and heart disease Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases Patients with an ICD Susanne S. Pedersen, Professor of Cardiac Psychology.

CoRPS Center of Research on Psychology in Somatic diseases subjective cognitive functioning in patients with breast problems.

CoRPS Center of Research on Psychology in Somatic diseases Type D personality as a risk factor for adverse vascular outcomes in diabetes patients: A role.

CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.

CoRPS Center of Research on Psychology in Somatic diseases Tilburg University The Netherlands Predictors of posttraumatic stress (PTSD) 18 months post.

CoRPS Center of Research on Psychology in Somatic diseases The patient perspective on LVAD implantation – a neglected dimension? Prof. dr. Susanne S. Pedersen,

CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.

Correlates of Patient Acceptance of the Cardioverter-Defibrillator: Cross-validation of the Florida Patient Acceptance Survey in Danish Patients Correlates.

Date of download: 6/26/2016 From: Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter- Defibrillator Among Patients.

CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.

CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.

CoRPS Center of Research on Psychology in Somatic diseases ICD patients with anxiety: what to do? Susanne S. Pedersen, Professor of Cardiac Psychology.

Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.

Wearable Cardioverter Defibrillators

Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.

Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.

Implantable Defibrillator Therapy Post Cardiac Arrest

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.

The ADEMEX Trial Adequacy of PD in Mexico Reference

Deactivating the shocking component of an Implantable Cardioverter Defibrillator (ICD) (When no longer appropriate)

Annual Outcomes With Transcatheter Valve Therapy

Annual Outcomes With Transcatheter Valve Therapy

Preventing SCD With a WCD: Reviewing the Results of the VEST Trial

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Gaurav A. Upadhyay, MD, Jonathan S. Steinberg, MD Heart Rhythm

David D. Berg et al. JACC 2018;71:

Belinda Gray et al. JCHF 2013;1:

Prognostic importance of distressed (Type D) personality and shocks in patients with an implantable cardioverter defibrillator Johan Denollet, Fetene.

Mahesh Anantha Narayanan et al. JACEP 2017;3:

Volume 14, Issue 3, Pages (March 2017)

Mahesh Anantha Narayanan et al. JACEP 2017;j.jacep

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep

Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.

Presentation transcript:

Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac Psychology

Affiliations 1.Department of Medical Psychology and Neuropsychology, Center of Research on Psychology in Somatic diseases (CoRPS), Tilburg University, the Netherlands 2.Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands 3.Department of Cardiology, Odense University Hospital, Denmark

Background The implantable cardioverter defibrillator (ICD) is superior to anti-arrhythmic drugs for the prevention of sudden cardiac death Established treatment both as primary and secondary prophylaxis → expansion of indications Concerns of clinicians and patients about the impact of the ICD on patient-centered outcomes, particularly as primary prophylaxis treatment ACC/AHA/ESC Guidelines. Circulation 2006;114:e385-e484

Patients with a primary indication for the ICD differ from secondary indication patients: –may fail to understand why they need the device (e.g. if survived several years post MI) –fears of device malfunction, advisory, and complications, incl. inappropriate shocks Conviction of cardiologists: –Primary indication has been described as “one of the more confusing and poorly understood consultations cardiologists perform” Zimetbaum. JAMA 2007; 297:1909–1916 Pedersen, Sears, Burg, van den Broek. PACE 2009;32:

Viewpoint – indication and patient- centered outcomes Pedersen, Sears, Burg, van den Broek. PACE 2009;32:

Objective To examine the influence of indication (primary versus secondary) on disease- specific and general anxiety

Methods: Patient sample Consecutive cohort (N = 312) of patients implanted with an ICD between August 2003 to December 2008 at the Erasmus Medical Center, Rotterdam, the Netherlands Derived from the ongoing Mood and personality as precipitants of arrhythmia in patients with an Implantable cardioverter Defibrillator: A prospective Study (MIDAS)

Methods: Procedure Patients completed a set of standardized questionnaires at three time points: –Baseline (one day prior to ICD implantation) –10 days post implantation –3 months post implantation

Methods: Measures Demographic and clinical: Information derived from medical records and purpose- designed questions in the questionnaire Number of ICD therapies (ATPs and ICD shocks) were obtained by means of device interrogation Psychological: The 8-item ICD Patient Concerns questionnaire (e.g. “I am worried about not having any warning that my ICD will fire”) The 20-item State-Trait Anxiety Inventory (state measure) (e.g. “I feel nervous”)

Results: Sample characteristics Secondary indication: = 37.5% (117/312) Mean age = 57.7 ± 12.3 Men = 80.1% (250/312) Heart failure = 38.1% (119/312) Ischemic etiology = 59.3% (185/312) ICD shock (appropriate and/or inappropriate) during 3-month follow-up = 6.1% (19/312)

Results: Mean scores on patient ICD concerns Main effect: p<.001; all comparisons at all time points (all ps<.001) Time effect: p<.001 Time by indication: p<.27 ICDC score range: 0-32 ANOVA with repeated measures

Results: Mean scores on general anxiety Main effect: p<.13 Time effect: p<.001 Time by indication: p=.87 STAI score range: ANOVA with repeated measures

Results: Indication and ICD concerns (adjusted)* PredictorF-testP Secondary indication Age Sex Atrial fibrillation Ischemic etiology Heart failure Shock during follow-up * ANCOVA with repeated measures

Results: Shock and ICD concerns No shock during follow-upShock during follow-up Primary Secondary -----

Conclusions Patients with an ICD due to secondary prophylaxis experienced more device concerns than primary prophylaxis patients No differences between groups on general anxiety Patients receiving a shock during follow-up, irrespective of indication, reported more ICD concerns

Conclusions Generic measures of anxiety may not be sufficiently sensitive to measure the impact of indication on patient-centered outcomes Monitor ICD patients from the time of implantation for distress – use of a disease- specific measure Intervene if symptoms do not abate – consequences for risk of future therapies and mortality Van den Broek, Denollet et al. JACC 2009;54: Pedersen, Theuns, Jordaens et al. Submitted

WEBCARE

Acknowledgements Collaborators: Dominic AMJ Theuns, PhD (EMC) Luc Jordaens, MD, PhD (EMC) Agnes JQ Muskens-Heemskerk (EMC) Ruud AM Erdman, PhD (EMC) Funding to Dr. SS Pedersen: VENI grant ( ) from the Netherlands Organisation for Scientific Research (NWO) VIDI grant ( ) from the Netherlands Organisation for Health Research and Development (ZonMw)